Combined transcriptional, translational and cell surface targeted gene therapy of HER2-positive breast cancer stem cells in three-dimentional cell culture

Cobra Moradian
Tarbiat Modares University

Fatemeh Rahbarizadeh (rahbarif@modares.ac.ir)
Tarbiat Modares University

Research Article

Keywords: Breast Cancer Stem Cell (BCSC), Mammosphere, PE38, PAMAM, Anti-HER2 nanobody, Hanging drop

DOI: https://doi.org/10.21203/rs.3.rs-184507/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Purpose

Breast Cancer Stem Cells (BCSCs) resist conventional treatments and cause tumor recurrence. Almost 25% of breast cancers overexpress human epidermal growth factor receptor-2 (HER2). Here we developed a novel multi-targeted nanosystem to specifically eradicate HER2-positive BCSCs.

Methods

Plasmids containing CXCR1 promoter, PE38 toxin and 5′UTR of the basic fibroblast growth factor-2 (bFGF 5′UTR) were constructed. Polyamidoamine (PAMAM) dendrimers functionalized with an anti-HER2 VHH were used for plasmid delivery. Stem proportion of MCF-10A and MDA-MB-231/HER2⁺ (a cellular model of HER2 overexpression, developed in our lab) were evaluated by mammosphere formation assay. Hanging drop technique was used to produce spheroids. The uptake, gene expression and killing efficacy of the multi-targeted nanosystem were evaluated in both monolayer and spheroid culture.

Results

MDA-MB-231/HER2⁺ had more than 3 times higher ability to form mammosphere compared to MCF-10A, representing higher stem proportion in MDA-MB-231/HER2⁺. In hanging drop culture, MDA-MB-231/HER2⁺ generated compact well-rounded spheroids, while MCF-10A failed to form compact cellular masses. The multi-targeted nanosystem showed much better uptake, higher PE38 expression and subsequent cell death in MDA-MB-231/HER2⁺ compared to MCF-10A. However efficacy of our targeted toxin gene therapy were lower in MDA-MB-231/HER2⁺ spheroid than those in monolayer.

Conclusions

Our novel multi-targeted nanosystem resulted in synergistic cytotoxic effects in HER2-positive BCSCs. This results demonstrate the necessity to use a combinatorial tumor targeting approach, to restrict the expression of a killer gene to target cells. Lower efficacy of our targeted gene therapy in spheroid models vs. monolayer culture suggest that, anticancer therapy assessments using spheroid might be more predictive of clinical efficacy than conventional monolayer culture.

Introduction

BCSCs are a subpopulation of breast cancer cells with selfrenewal and differentiation capacity. Since BCSCs resist conventional treatments and cause tumor recurrence, targeting them may lead to the development of more effective cancer therapies. BCSCs survive and generate mammosphere in low-
adherence serum-free cultures, whereas all the other cell types will undergo anoikis. Each mammosphere represents on average one stem cell of the parental population. Based on this feature, we used mammosphere formation assay to determine the proportion of BCSCs in MDA-MB-231/HER+ as well as BCSC-like cells in pseudonormal MCF-10A.

Targeted killer gene therapy is a promising approach for eradicating cancerous cells. Here, we utilized CXCR1 promoter, PE38 toxin and bFGF 5'UTR genetic construct delivery using PAMAM dendrimers functionalized with an anti-HER2 VHH to target HER2-positive BCSCs on transcriptional, translational and cell surface levels simultaneously.

PE38 is a mutated form of *Pseudomonas* exotoxin A. This highly cytotoxic protein arrests protein synthesis by inactivating eukaryotic elongation factor-2 (eEF-2). To date, many studies have reported that the introduction of PE38 rapidly kills the host cells. In this research we utilized CXCR1 promoter to restrict PE38 transcription to BCSCs and HER2-positive breast cancer cells. CXCR1, a receptor for interleukin-8, is overexpressed in aforementioned cells.

With the aim of translational targeting, bFGF 5'UTR was used as an additional discriminatory element to the CXCR1 promoter to improve the stringency and specificity of the treatment. Translation of mRNAs with long and highly structured 5'UTRs is largely dependent on the unwinding activity of eukaryotic translation initiation factor 4E (eIF4E). Eukaryotic IF4E is rare in most cell types. Nonetheless, it is overexpressed in tumorigenic cells and facilitates the translation of GC-rich 5'UTR of the bFGF.

PAMAM dendrimers are attractive vehicles for gene delivery. They effectively condense Nucleic acids and protect them from being degraded by nucleases. In order to avoid off-target effects, dendrimers can be equipped with a variety of tumor-specific targeting agents such as peptides, aptamers, antibodies and VHHs. VHH is the smallest antigen-binding domain of Camelidae heavy chain antibodies. Their unique characteristics including exquisite affinity and specificity against their targets, high stability and solubility as well as low immunogenicity make them ideal targeting agents for cancer killer gene therapy. With the aim of cell surface targeting, we functionalized PAMAM dendrimers with an anti-HER2 VHH.

Almost 25% of breast cancers overexpress HER2. HER2 overexpression confers a higher rate of aggressive metastasis and mortality by expanding the BCSC population as well as increasing the tumorigenicity and invasiveness of this population. HER2 is expressed in both bulk tumor and BCSC populations. Some reports suggest that in HER2-negative breast cancers, HER2 may be selectively expressed in breast cancer stem cells but not bulk cell populations. It is assumed that, the considerable therapeutic benefit of HER2-targeting agents (ex. Trastuzumab) might be due to their BCSC targeting capability.

In this study, we exploited the potential of our multi-targeted nanosystem in both monolayer and spheroid culture. Unlike monolayer culture, 3D spheroid culture recaptures many features of the real tumor, such as
cell–cell contact, cell–extracellular matrix (ECM) interactions as well as oxygen, nutrient and signal gradients. Hanging drop is an efficient method for cultivating spheroids with uniform size and shape. We utilized the Hanging drop technique to prepare 3D spheroids. One distinct advantage of this technique over other spheroid culture methods, is that this method avoids using uncontrolled mechanical forces and interference from exogenous materials. Indeed, cells accumulate at the bottom of the drop under gravity, secrete their own matrix components and self-assemble into spheroid. These features offer a great potential to study the effect of antitumor treatments\textsuperscript{19}. Of note, this study is the first example of in situ transfection of spheroid in hanging drop culture.

**Materials And Methods**

**Materials**

PE38 encoding plasmid (pRB391) was a kind gift from Prof. Ira Pastan (NIH). PAMAM G5 dendrimer and 2, 4, 6-trinitrobenzene sulfonic acid (TNBSA) were purchased from Sigma-Aldrich (St Louis, MO, USA). Traut’s reagent (2-Iminothiolane-hydrochloride) was obtained from Pierce (Rockford, IL, USA). NHS-PEG3500-MAL was purchased from Jenkem Technology (Beijing, China). MDA-MB-231 were obtained from DSMZ (Braunschweig, GERMANY). MDA-MB-231/HER2\textsuperscript{+} is a cellular model of HER2 overexpression, developed in our lab via lentiviral transduction as described previously\textsuperscript{20}. MCF-10A, were purchased from ATCC (Manassas, VA). All other reagents used in this study were of analytical grade and bought from Sigma-Aldrich Co.

**Anti-HER2 VHH production, expression and purification**

The anti-HER2 VHH clone were isolated from a large nanobody library from a one-humped and a two-humped immunized camels, using phage display technique\textsuperscript{21}. The nucleotide sequence was sub-cloned into PET28, expressed in *E. coli* and purified using immobilized metal ion affinity chromatography (IMAC) column, as described previously\textsuperscript{22}.

**Gene Constructs**

The methods of making the gene constructs has been described in detail previously\textsuperscript{23}. Briefly, CMV promoter was PCR amplified from pGL4.50 (Promega, WI). The PCR product was sub-cloned into the pGL4.14 vector (Promega) to make pGL4.14-CMV (pG-CM).

For cloning of CXCR1 promoter, 1123 bp fragment surrounding the putative promoter region of upstream of CXCR1 gene was amplified by PCR from peripheral lymphocytes DNA. The PCR product was inserted into upstream of the luciferase gene in pGL4.14 to make pGL4.14-CXCR1 (pG-CX).

For cloning of bFGF 5'UTR, 400 bp of 5’ region of human bFGF mRNA sequence (chromosome 4q26; NG_029067.1; Gene ID: 2247) was selected. This fragment, flanked by *Nhe*I and *Bgl*II sites, was
synthesized by Life Technology (Invitrogen, CA, USA) and received in pMK-RQ, then it was sub-cloned into pG-CX to make pGL4.14-CXCR1-bFGF 5'UTR (pG-CX-bF).

PE38 gene was amplified from pRB391 by PCR. The PCR product was substituted for luciferase gene of pG-CM, pG-CX and pG-CX-bF to make pGL4.14-CMV-PE38 (pG-CM-PE), pGL4.14-CXCR1-PE38 (pG-CX-PE) and pGL4.14-CXCR1-bFGF 5'UTR-PE38 (pG-CX-bF-PE) respectively.

The constructs were purified using the endotoxin-free plasmid DNA purification kit (MACHEREY-NAGEL), validated by sequencing and then used for cell transfections.

**Preparation of VHH-PEG-PAMAM and Trastuzumab-PEG-PAMAM conjugates**

G5 PAMAM was reacted with NHS-PEG3500-Mal in 2 mL of degassed phosphate buffer (pH 7.5) at a ratio of 1:10 (mol/mol) under N2 atmosphere at room temperature with gentle shaking for 2 h. Removal of unreacted PEG molecules was carried out by ultrafiltration using Amicon ultrafilters (MWCO 10 kDa; Millipore, Schwalbach, Germany). The number of PEG groups introduced to PAMAM was determined based on TNBSA assay.

For conjugation of the anti-HER2 VHH to maleimide distal end of PEGylated PAMAM dendrimers, the anti-HER2 VHH were first thiolated using Traut’s reagent. Traut’s reagent was added to the anti-HER2 VHH in borate buffer (50 mM sodium borate, 0.1M EDTA, pH 8.3), to produce a ratio of 1:10 (mol/mol), and the reaction was performed under N2 atmosphere at room temperature with gentle shaking for 1 h. Removal of unbound Traut molecules and replacing the buffer with phosphate buffer were carried out by ultrafiltration using Amicon ultrafilters (MWCO 30 kDa).

Thiolated VHH was added to the PEG-PAMAM to produce a ratio of 2:1 (mol/mol), and the reaction was performed under N2 atmosphere at room temperature with gentle shaking for 18 h. The final conjugates (VHH-PEG-PAMAM) were purified using Amicon ultrafilters (MWCO 50 kDa), lyophilized and stored at −80°C.

All the procedures of preparing Trastuzumab-PEG-PAMAM conjugates were the same as the synthesis of VHH-PEG-PAMAM conjugates except that the molar ratio of Traut reagent to Trastuzumab were (20:1) and removal of unbound Traut molecules were carried out by Amicon ultrafilter with a bigger pore size (MWCO 100 kDa).

From now on, PEG-PAMAM, VHH-PEG-PAMAM and Trastuzumab-PEG-PAMAM will be referred to as PG-PAM, VHH-PG-PAM and Tra-PG-PAM, respectively.

**Characterization of PG-PAM and VHH-PG-PAM conjugates**

**Measuring primary amines of PAMAM and PEGylated PAMAM**
The primary amine group content of PAMAM and PEGylated PAMAM was measured with a spectrophotometer after reaction of the free amine groups with TNBSA, as described by Snyder et al.\textsuperscript{24}. The standard curve was generated by the use of glycine serial dilutions (data not shown). The quantity of PEG groups coupled to the PAMAM were calculated by the differences in the amounts of primary amines on PAMAM and PEGylated PAMAM.

**Characterization of PG-PAM by FTIR**

To verify the PEGylation, 1 mg of unmodified G5 PAMAM and PG-PAM conjugates were analyzed by FTIR (Perkin Elmer instrument) at a resolution of 4.0 cm\(^{-1}\) via the KBr pellet method.

**Characterization of VHH-PG-PAM conjugates by H-NMR**

VHH-PG-PAM conjugate was characterized by nuclear magnetic resonance spectroscopy (NMR) using Bruker 400 MHz Avance II + H-NMR spectrometer (Bruker, Rheinstetten, Germany) in deuterium water (D\(_2\)O).

**Dendriplex formation**

Plasmid DNA and dendrimer solutions were prepared in HEPES-buffered glucose (HBG; HEPES 20 mM, Glucose 5% w/w, pH 7.4). Dendriplexes were prepared by mixing equal volumes of plasmid DNA solutions and PAMAM, PG-PAM, VHH-PG-PAM or Tra-PG-PAM solutions at the N/P ratio of 10. The mixtures were vortexed for 30 s and left for 30 min at room temperature. Table 1 lists the prepared nanoparticle/gene construct complexes and the corresponding abbreviations.

| Test                   | Nanoparticle/Gene construct complexes                        | Abbreviation    |
|------------------------|-------------------------------------------------------------|-----------------|
| Cellular uptake        | PAMAM/pEGFPN1                                               | PAM/GFP         |
| PE38 mRNA Expression   | PEG-PAMAM/pEGFPN1                                           | PG-PAM/GFP      |
| and                    | VHH-PEG-PAMAM/pEGFPN1                                        | VHH-PG-PAM/GFP  |
| PE38 cytotoxicity      | PAMAM/pGL4.14                                               | PAM/pGL4.14     |
|                        | PAMAM/pGL4.14-CMV-PE38                                       | PAM/pG-CM-PE    |
|                        | VHH-PEG-PAMAM/pGL4.14-CMV-PE38                               | VHH-PG-PAM/pG-CM-PE |
|                        | VHH-PEG-PAMAM/pGL4.14-CXCR1-PE38                             | VHH-PG-PAM/pG-CX-PE |
|                        | VHH-PEG-PAMAM/pGL4.14-CXCR1-bFGF 5'UTR-PE38                  | VHH-PG-PAM/pG-CX-bF-PE |

**Dendriplex characterisation**
Gel retardation assay

Binding of the pG-CX-bF-PE to PAMAM, PG-PAM, VHH-PG-PAM were corroborated by agarose gel retardation assay. PAMAM or its conjugates were complexed with 1 µg plasmid at the N/P ratio of 10, and an amount of 1 µg free plasmid as a control, were run in the 1% agarose gel prepared in 1 M Tris-acetate-EDTA (TAE) buffer solution and stained simultaneously with Ethidium Bromide and Bromophenol Blue. Electrophoresis was performed at 100 constant volts for 30 min.

Dynamic light scattering and zeta potential measurements

PAM/pG-CX-bF-PE, PG-PAM/pG-CX-bF-PE and VHH-PG-PAM/pG-CX-bF-PE dendriplexes were prepared according to the method mentioned in Dendriplex formation section and diluted by 800 µL of Milli-Q water. Their size and surface charge were measured by Zetasizer Nano ZS (Malvern Instruments, Malvern, UK).

Atomic force microscopy

The shapes and particle sizes of the VHH–PG–PAM/pG-CX-bF-PE were analyzed using atomic force microscopy. Dendriplexes were prepared using VHH-PG-PAMAM complexed with pG-CX-bF-PE at N/P ratio of 10 and incubated for 15 min at RT. The dendriplex solution was then diluted 1:20 with MilliQ-water. After that, a volume of 5 µL of the solution were placed on a freshly cleaved untreated mica surface and allowed to stick for 5 min. Then, the excess of sample were removed by careful absorption onto filter paper and the mica surface were further dried under a gentle stream of air at RT. Sample were examined with a JPK AFM (JPK Instruments Co., Germany) using contact mode, HYDRA6V-100N cantilever with pyramidal shape tip, force constant of 0.292 N/m, and resonance frequency of 66 kHz.

Transmission electron microscopy

Transmission electron microscopy (TEM) images were obtained from CEM 902A ZEISS (Jena, Germany) transmission electron microscope with an accelerating voltage of 80 kV, to investigate the size and morphology of the VHH-PG-PAM/pG-CX-bF-PE at N/P ratio of 10.

Flow cytometry analysis to determine Percentage of HER2 expressing cells

Flow cytometry was used to evaluate MCF10A, MDA-MB-231 and MDA-MB-231/HER2⁺, for the expression of HER2 marker. To this purpose, 70%-80% confluent cells were washed twice with phosphate-buffered saline (PBS) and then harvested with trypsin 0.05% (Thermo Fisher Scientific, USA). Detached cells were pelleted and re-suspended in phosphate-buffered saline supplemented with 0.5% fetal bovine serum (1×10⁶ cells/50 µl). FITC-conjugated anti-ErbB2 antibody (Abcam, Cambridge, UK) was added to the cell suspension and incubated at 4ºC in the dark for 30 min. Isotype control cells were incubated with FITC-conjugated mouse IgG (Abcam). The labeled cells were analyzed on a FACS Aria II Calibur (BD Biosciences). Data were analyzed with the Flowjo software version 7.2.4 (Tree Star Inc).
Mammosphere cultivation

Mammospheres were generated from $2 \times 10^4$ single cells seeded in 6-well tissue culture plates coated with 1.5% agarose; containing 2 ml DMEM/F12 (GIBCO) without serum, supplemented with B27 (1:50, Invitrogen), 5 mg/ml insulin (Sigma), 20 ng/ml bFGF (R&D) and 20 ng/ml EGF (R&D). Cultures were incubated in a humidified atmosphere at 37°C and 5% CO2 for 3 days without moving or disturbing the plates. After 3 days 400 µl of fresh media was added to each well (without removing the old media). Mammospheres were imaged on day 7. The size and number of mammospheres were quantitated using ImageJ software (NIH, USA). Mammosphere formation efficiency (MFE) was calculated as (the number of mammospheres per well (diameter > 50 µm) divided by the original number of single cells seeded per well) × 100. Experiments were done in duplicates.

Monolayer Cell Culture

MDA-MB-231 and MDA-MB-231/HER2+ were maintained in RPMI-1640 medium with 10% (v/v) FBS and penicillin/streptomycin. MCF10A were grown in DMEM-F12 medium (Invitrogen) containing Hydrocortisone (0.5 µg/ml), Insulin (10 µg/ml), EGF (20 ng/ml), Horse serum 5% (v/v) (Gibco), and penicillin/streptomycin. All cell lines were maintained in a humidified incubator at 37°C and 5% CO2.

Monolayer Cell transfection

For cell transfection, $6 \times 10^4$ cells/well were seeded and incubated until they reached ~80% confluency. Immediately before transfection, the complete medium was removed, cells were washed with PBS, fresh medium without serum and antibiotics was added to each well. The dendriplexes were prepared freshly prior to use and 100 µL of dendriplex solution at a final transfection DNA concentration of 2 µg /mL$^{-1}$ were applied to cultured cells. After 6 h incubation, the transfection solution was removed, cells were washed with PBS, cell-specific complete medium was added and the culture was further incubated for the time period required for each experiment.

Hanging drop culture

MCF-10A and MDA-MB-231/HER+ Cell lines were cultured as spheroids in their appropriate media by the hanging drop method. Cells were dissociated from a monolayer cell culture, counted and resuspended in complete medium at a concentration of $3 \times 10^4$ cells/ml. Thirteen µl aliquots of the suspension (containing 1000 cells each) were deposited on the underside of a 10 cm petri dish lid. The lid was then inverted over the dish filled with 10 ml of PBS (to keep the cells hydrated). The dish was maintained at 37°C in a humidified incubator with 5% CO2 for 7 days. The growth media were exchanged every other day by up-righting the lid, taking 10 µL media from each drop and adding 14 µL fresh media into it. Cells were imaged daily and spheroid` s size (average of the major and minor axis length) was measured using the NIH ImageJ software.

Spheroid transfection
On the seventh day following spheroid generation, the complete medium was replaced with PBS and subsequently with fresh medium without serum and antibiotics, using sequential pipetting method. The dendriplexes were prepared freshly prior to use and were carefully introduced to the individual spheroids by taking 14 µL media from each drop and adding 14 µL of dendriplex solution to them. After 6 h incubation, the medium was replaced with the complete medium, using the sequential pipetting method. The hanging drop culture was further incubated for the time period required for each experiment. Transfected spheroids were then collected and dissociated to single cells by pipetting through a 200 µl pipet tip. The obtained single cells were used for cellular uptake, PE38 mRNA Expression or cytotoxicity assays as described in subsequent Methods sections. For each assay, three identical experiments were performed and 20 spheroids were analyzed per condition.

**Cellular uptake**

To evaluate gene transfection efficiency of dendrimeric constructs in different cell lines, dendriplexes of pEGFPN1 and PAMAM, PEG-PAMAM, VHH-PEG-PAMAM or Trastuzumab-PEG-PAMAM were prepared as described in the “Dendriplex formation” section. MCF-10A, MDA-MB-231, MDA-MB-231/HER2⁺ and MDA-MB-231/HER2⁺ spheroid were transfected with the aforementioned dendriplexes. Forty-eight hours after transfection, the GFP expression was analyzed using a fluorescence microscope (Carl Zeiss, NY).

**Analysis of PE38 mRNA Expression**

Sixteen hours after transfection with different dendriplexes, cells were collected, the total RNAs were isolated with the High Pure RNA Isolation kit (Roche), reverse transcribed using M-MuLV reverse transcriptase and oligo-dT (Fermentas).

Real-time PCR were performed by Rotorgene 3000 series PCR machine (Corbett Research, San Francisco, USA) using RealQ Plus 2x Master Mix Green (Amplicon, Denmark). All mRNA quantification data were normalized to β-actin. The primers for amplifying PE38 and beta-actin were as follows: PE38 for: 5′ AGGACCTCGACGCGATCTG, PE38 Rev: 5′ TCAGCTCGTGCCGGTTAGAAG, β-actin for: 5′ TCC CTGGAGAAGCTACG and β-actin Rev: 5′ GTAGTTTCTGGATGCCACA. Relative PE38 mRNA expression in different samples were calculated by Pfaffl method. The assay was repeated three times.

**Cytotoxicity study**

To evaluate PE38 cytotoxicity, cell viability of transfected cells vs. non-transfected cells were determined by MTT assay. Briefly, cells were seeded and transfected as described for monolayer or spheroid culture, 6 h after transfection with different dendriplexes, transfection solution was removed, cells were washed with PBS and complete medium was added to each well. After 48 hours incubation, the complete medium was replaced by the fresh medium without serum and antibiotics, then 1 mg/mL MTT reagent (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Sigma) was added to each well and followed as the manufacturer recommended. The assay was repeated three times.

**Statistical analysis**
The statistical analysis was performed using GraphPad PRISM v.6.01 (GraphPad Software Inc, CA, USA). All data subjected to statistical analysis were obtained from at least three parallel experiments. Unpaired Student’s t-test was used to determine significant differences between each group. Two-way ANOVA with Tukey’s multiple comparison post hoc test was used to determine significant differences between different groups. A $p$-value $\leq 0.05$ was considered statistically significant.

**Results And Discussion**

**Characterization of PG-PAM and VHH-PG-PAM conjugates**

**Measuring primary amines of PAMAM and PEGylated PAMAM**

TNBSA assay confirmed that PEGylation of dendrimers with molar ratios of 10 yielded conjugates containing an average of 19 PEG chains per PAMAM molecule.

**Characterization of PG-PAM by FTIR**

The formation of PG-PAM conjugates was further confirmed by FTIR spectra. In FTIR spectra (Fig. 1a), the peak at 3300 cm$^{-1}$ due to –NH– groups of PAMAM stretching vibration is evident. The characteristic peaks of methyl C = O stretching of carbonyl groups of PAMAM internal amides or PG–PAM amide bonds is found at 1650 cm$^{-1}$. Besides, the peak at 1110 cm$^{-1}$ due to stretching vibration of –CH2–O–CH2– etheric bonds of PEG molecules, indicating that PEG chains are successfully attached to PAMAM dendrimers.

**Characterization of VHH-PG-PAM conjugates by H-NMR**

The successful synthesis of VHH-PG-PAM was confirmed by H-NMR (Fig. 1b). The PAMAM dendrimer showed multiple peaks between 2.3 and 3.3 ppm such as $\delta$ 2.2–2.5 (–CH2CH2CONH–); $\delta$ 2.6 (–CH2CH2N<) and $\delta$ 3.2–3.3 (–CONHCH2CH2–). The peaks between 3.5 and 3.6 ppm belong to the (–CH2CH2O–) units of PEG chains. The VHH showed peaks between 7 and 8 ppm related to the benzene rings of aromatic amino acids in VHH protein sequence, indicating the successful conjugation of the VHH and PAMAM.

**Dendriplex characterisation**

**Gel retardation assay**

Agarose electrophoretic mobility retardation assay was performed using PAM/pG-CX-bF-PE, PG-PAM /pG-CX-bF-PE and VHH-PG-PAM/pG-CX-bF-PE, at N/P ratio of 10. The purified pG-CX-bF-PE plasmid moved toward anode (Fig. 2a, lane 1). In contrast, Fig. 2a, lanes 2 shows that, not only PAMAM reversed the plasmid electrophoresis pattern, but also the negatively charged Bromophenol Blue dye were also
electrophoresed to the opposite direction, cathode. This result suggest that the overall charge of PAM/pG-CX-bF-PE were comparatively positive. Figure 2a, lanes 3 and 4 show that, PG-PAM and VHH-PG-PAM interacted sufficiently with the pG-CX-bF-PE and neutralized its negative charge so the plasmid were retarded in the well.

**Dynamic light scattering and zeta potential measurements**

The size and zeta potential of the dendriplexes at N/P ratio of 10 were measured by zetasizer Nano ZS. According to results presented in Table 2, all the dendriplexes showed the appropriate size and charge density. Low polydispersity indexes indicate the formation of homogeneous and aggregate free dendriplexes.

It seems that by conjugating PEG and VHH to the PAMAM dendrimers, the size of dendriplexes increased, while the zeta potential were decreased. These findings imply that both PEG and VHH were successfully attached to the dendrimers and shielded the positive charges of the free amines on the PAMAM surface. However, the size of dendriplexes ranged between 105.6 and 154.7 nm and the zeta potential ranged between 26.8 and 5.2 mV which are considered to be appropriate for endocytosis.

| Dendriplex                  | PDI | Size (nm) | zeta potential (mV) |
|-----------------------------|-----|-----------|---------------------|
| PAM/pG-CX-bF-PE             | 0.16| 105.6     | 26.8                |
| PG-PAM/pG-CX-bF-PE          | 0.24| 127.4     | 11.4                |
| VHH-PG-PAM/pG-CX-bF-PE      | 0.21| 154.7     | 5.2                 |

**Atomic force microscopy**

The morphology of VHH-PG-PAM/pG-CX-bF-PE at an N/P ratio of 10, were observed by AFM (Fig. 2b). The result obtained revealed that the dendriplexes formed spherical particles with an average diameter of $121 \pm 2$ nm and a narrow size distribution, falling within the optimum size requirements ($100–200$ nm) for efficient cellular endocytosis.

**Transmission electron microscopy**

Transmission electron microscopy was performed to further investigate the size and morphology of VHH-PG-PAM/pG-CX-bF-PE dendriplexes. TEM result was in accordance with the AFM data, showing spherical structures with an average particle size of $118 \pm 7$ nm (Fig. 2c). However, the particle size visualized by TEM and AFM were smaller than those determined by DLS. The most probable explanation would be that TEM and AFM determine the dry particle size, whereas DLS reflects the hydrodynamic size.

**Percentage of HER2 expressing cells**
MCF10A, MDA-MB-231 and MDA-MB-231/HER2+ cell lines were analyzed using flow cytometry for HER2 expression. As illustrated in Fig. 3a and b, MCF10A and MDA-MB-231 demonstrated a weakly positive HER2 expression (1.12% and 1.89% respectively). Whereas, 99.00% of MDA-MB-231/HER2+ cells expressed HER2 cell surface marker (Fig. 3c).

There is discernible differences in BCSC pools between MCF-10A and MDA-MB-231/HER2+

Mammosphere assay was used to evaluate the stem property of the cell lines. According to Fig. 4a, both cell lines had the ability to form compact mammospheres. MCF-10A generated small round spheres, whereas MDA-MB-231/HER2+ formed large irregular shapes. However, after one week under mammosphere culture, clear variations in MFE of MCF-10A (0.5 ± 0.11%) and MDA-MB-231/HER2+ (1.8 ± 0.43%) were observed, representing higher BCSC pool in MDA-MB-231/HER2+.

Mammosphere formation assay identifies BCSCs based on their resistance to anoikis in non-adherent/serum-free conditions. This technique is considered to be more solid than conventional BCSC specific marker identification since cell surface markers vary infinitely from one breast cancer cell to another25.

Morphology of spheroids in hanging drops.

We utilized the hanging drop technique to generate spheroids with uniform shape and size. MCF-10A grown in hanging drop culture formed thoroughly loose aggregates exposing free areas between the cells. While MDA-MB-231/HER+ generated tightly compact well-rounded spheroids within 24 hours (Fig. 4b). Based on these results, MCF-10A aggregates were excluded from further investigation and MDA-MB-231/HER+ spheroids were selected for subsequent studies.

MDA-MB-231/HER+ spheroids were maintained in hanging drop culture for 7 days and imaged daily. As illustrated in Fig. 5, spheroids of different drops were consistent in both size and shape. On the first day spheroids measured approximately 203 µm. From first to sixth day the spheroids diameter increased slightly. On the sixth day their average size reached to 484 µm. However, by day 7 it decreased to 439 µm, indicating spheroids started to become denser. Several researchers suggest that spheroids of diameter ranging between 300 and 500 µm accurately mimic real tumors26–28.

As it can be seen in Fig. 5, with increasing length of hanging drop culture, spheroids became a little darker in color, which is an indicative of gradual compactness29.

On the seventh day following hanging drop culture, spheroids were transfected with the previously mentioned dendriplexes. It is noticeable that, spheroids were washed and transfected while they were in the drops, which to the best of our knowledge has not been previously accomplished.
Next, the transfected spheroids were used to evaluate the discrimination of our treatment efficacy in MDA-MB-231/HER2⁺ monolayer and spheroid culture.

Anti-HER2 VHH functionalization improved cellular uptake in the HER2 overexpressing cell line.

Fluorescence microscopy was employed to compare the uptake efficiency of dendrimers and evaluate targeting efficiency of the anti-HER2 VHH. As it can be seen in Fig. 6, unmodified PAMAM transfection efficacy were comparable in all the three cell lines. However, PEGylation suppressed the cellular uptake to some extent. Similarly, Fant et al. reported that PEGylation of PAMAM dendrimers reduced its transfection efficacy. In fact, PEGylation reduces the transfection efficacy of cationic dendrimers, yet increases their biocompatibility, probably by lowering their surface positive charge.

In MCF-10A and MDA-MB-231, VHH-PG-PAM, as well as Tra-PG-PAM, showed lower uptake as compared to PAM. In contrast, the transfection capability of these two targeted conjugates was significantly higher in MDA-MB-231/HER2⁺ (both monolayer and spheroids). However, differences between VHH-PG-PAM and Tra-PG-PAM transfection efficacy were negligible.

Both conjugated and non-conjugated dendrimers were likely taken up by MCF-10A and MDA-MB-231 via non-specific electrostatic interactions with the cell surface. The unexpected lower transfection efficacy of VHH-PG-PAM, as well as Tra-PG-PAM, as compared to PAM in low/non-HER2 expressing MCF-10A and MDA-MB-231 cell lines might be attributed to the lower net positive charge and larger particle size of the conjugated dendrimers. Nevertheless, the superior transfection efficiency of the targeted dendrimers in MDA-MB-231/HER2⁺ was likely due to the HER2 receptor-mediated endocytosis rather than non-specific electrostatic interactions with the cell surface.

Comparison of MDA-MB-231/HER2⁺ grown as monolayer vs spheroid revealed that internalization of all the dendriplexes were significantly lower in the spheroids.

A possible reason for the lower uptake rate in spheroids might be the penetration resistance inherent in their structure. Spheroid is a three-dimensional (3D) model that closely resembles small avascular tumors and micrometastases in that they contain a proliferative outer shell, a relatively large zone of hypoxic quiescent cells and a relatively small necrotic area at the center. This 3D structure exhibit cell-to-cell and cell-to-matrix interactions as well as nutrient, pH and oxygen gradients. These characteristics make them proportional to penetration so that they are not efficiently transfected. This kind of resistance might not be observed when cells are cultured as monolayer.

In overall, VHH-PG-PAM gene delivery efficiency in the three cell lines followed the order of MDA-MB-231/HER2⁺ > MDA-MB-231/HER2⁺ spheroids > MCF-10A > MDA-MB-231. In overall, VHH-PG-PAM gene delivery efficiency in the three cell lines followed the order of MDA-MB-231/HER2⁺ > MDA-MB-231/HER2⁺ spheroids > MCF-10A > MDA-MB-231. From these results, it can be concluded that the anti-HER2 VHH...
modified PAMAM can be considered as an efficient gene and drug carrier to target HER2+ breast cancer cells.

Analysis of PE38 mRNA expression reveals efficient cell surface and transcriptional targeting.

MCF-10A, MDA-MB-231, MDA-MB-231/HER2+ and MDA-MB-231/HER2+ spheroid were transfected with PAM/pG-CM-PE, VHH-PG-PAM/pG-CM-PE, VHH-PG-PAM/pG-CX-PE and VHH-PG-PAM/pG-CX-bF-PE dendriplexes and their respective PE38 mRNA expression pattern were analyzed by real-time PCR. First, we will discuss the targeting efficacy of the different dendriplexes in the three cell lines (cultured as monolayer) together, then MDA-MB-231/HER2+ monolayer will be compared with its spheroid.

As illustrated in Fig. 7a, when transfected with PAM/pG-CM-PE (non-targeted), all the three cell lines expressed a high level of PE38 mRNA, with no significant differences among the cell lines ($p = \text{ns for all}$).

As expected, the level of PE38 mRNA exhibited variation between cell lines when the targeted dendriplexes were used. VHH-PG-PAM/pG-CM-PE (targeted at cell surface level) treated cells showed equally lower expression of PE38 mRNA in both low/non-HER2 expressing cell lines (MCF-10A and MDA-MB-231). Whereas, the expression increased significantly in MDA-MB-231/HER2+ ($p < 0.05$ for all). These observations confirm that the anti-HER2 VHH conjugation led to higher penetration efficiency of PAMAM dendrimers in the HER2 expressing cell line.

In case of VHH-PG-PAM/pG-CX-PE (targeted at cell surface and transcriptional level) treated cells as compared to VHH-PG-PAM/pG-CM-PE (targeted at cell surface level), the expression decreased in all the three cell lines, probably because CMV promoter is stronger than CXCR1 promoter. However, the reduction were more significant in MCF-10A ($p < 0.01$) compared to BCSC rich MDA-MB-231 and MDA-MB-231/HER2+ ($p < 0.05$ for both), probably due to the CXCR1 specificity for BSCSs and HER2 expressing breast cancer cells.

In addition, among the three cell lines transfected with VHH-PG-PAM/pG-CX-PE, the highest PE38 mRNA expression belonged to the MDA-MB-231/HER2+, indicating both good cell surface targeting and efficient transcriptional targeting.

There were no statistical differences in mRNA expression, between VHH-PG-PAM/pG-CX-PE and VHH-PG-PAM/pG-CX-bF-PE treated cells ($p = \text{ns for all}$), since bFGF 5′UTR modulate the gene expression specifically on translation level and not at the transcriptional level.

Comparison of MDA-MB-231/HER2+ grown as monolayer vs. spheroid revealed that, MDA-MB-231/HER2+ spheroid followed the same expression pattern as its monolayer, upon all the treatments, except the mRNA expression level were significantly lower in spheroids ($p < 0.001$), probably due to the lower cellular uptake as demonstrated by fluorescence microscopy. The low uptake of therapeutic agents in solid tumors is one of the major obstacles to the successful gene or drug delivery.
A combination of the cell surface, transcriptional and translational targeting, exerted a synergistic cytotoxic effect in HER2⁺ BCSCs.

MCF-10A, MDA-MB-231, MDA-MB-231/HER2⁺ and MDA-MB-231/HER2⁺ spheroids were transfected with the PAM/pG, PAM/pG-CM-PE, VHH-PG-PAM/pG-CM-PE, VHH-PG-PAM/pG-CX-PE and VHH-PG-PAM/pG-CX-bF-PE dendriplexes. The cytotoxic effect of PE38 on the transfected cells was evaluated using MTT assay.

First, we will discuss the cytotoxic effect of the different dendriplexes in the three cell lines (cultured as monolayer) together, then MDA-MB-231/HER2⁺ grown as monolayer and spheroid will be compared.

PAM/pG (empty vector) was used to determine the toxicity of the transfection process and as shown in Fig. 7b, the viability was about 80% in the three cell lines. In contrast, following treatment with PE38 encoding vectors, extensive cell death was detected. This result reveals the clear cytotoxic potential of this toxin.

However, having transfected with PAM/pG-CM-PE (non-targeted), all the three cell lines exhibited about 13% viability.

In the case of VHH-PG-PAM/pG-CM-PE (targeted on cell surface level), 28% and 24% cell viability for MCF-10A and MDA-MB-231 were detected, respectively; but it was 7% for MDA-MB-231/HER2⁺. These results suggest that VHH-PG-PAM/pG-CM-PE exerts potent cytotoxicity in HER2-overexpressing cells due to the specific cell surface targeting.

VHH-PG-PAM/pG-CX-PE exhibited higher viability rate, as compared to VHH-PG-PAM/pG-CM-PE in all the cell lines, showing that CXCR1 promoter is weaker than the commonly used strong CMV promoter. Cell viability of MCF-10A and MDA-MB-231 transfected with the VHH-PG-PAM/pG-CX-PE (targeted on cell surface and transcriptional levels) were 41% and 29%, respectively, while in the MDA-MB-231/HER2⁺ it was 11%. However, VHH-PG-PAM/pG-CX-PE demonstrated more viability variation between the cell lines compared to the non-specific CMV promoter, and the lowest viability belonged to the MDA-MB-231/HER2⁺, indicating CXCR1 promoter specificity for BSCSs and HER2 expressing breast cancer cells. These results also demonstrate that, combination of the cell surface and transcriptional targeting, exerted a synergistic targeting effect in HER2⁺ BCSCs.

When transfected with VHH-PG-PAM/pG-CX-bF-PE (targeted on cell surface, transcriptional and translational levels), MCF-10A and MDA-MB-231 exhibited 61% and 38% viability, respectively. But MDA-MB-231/HER2⁺ showed 15% recovery of the cells. Distinct viability variation between the cell lines, indicates the synergistic effect of these three targeting elements when combined together. It is noticeable that, viability of VHH-PG-PAM/pG-CX-bF-PE treated groups had a tendency to increase as compared to that of VHH-PG-PAM/pG-CX-PE treated groups, probably because the highly structured, GC rich 5' UTR of the bFGF hinders efficient translation. Translation of mRNAs with highly structured bFGF 5'UTR is particularly dependent on the unwinding activity of eIF4E. Higher levels of eIF4E in breast cancer cell...
lines, relative to non-malignant MCF10A cells have been reported previously\textsuperscript{34–36}. Thus, it can be concluded that overexpression of eIF4E in tumorigenic MDA-MB-231 and MDA-MB-231/HER2\textsuperscript{+} might be responsible for efficient toxin translation and subsequent massive cell death. Nonetheless, low levels of eIF4E in normal MCF-10A repressed toxin translation, resulting in elevated viability. Our study findings are consistent with other reports showing the efficient targeting efficacy of bFGF 5’UTR toward cancerous cells\textsuperscript{9,34,37}.

Comparison of MDA-MB-231/HER2\textsuperscript{+} grown as monolayer vs spheroid revealed that MDA-MB-231/HER2\textsuperscript{+} spheroid followed the same viability pattern as its monolayer, upon all the treatments, except the viability were significantly higher upon all the treatments ($p < 0.01$). These results further validated those obtained by cellular uptake and real-time PCR experiments. Indeed, previous studies have demonstrated a differential response to compounds when cells grown as spheroid compared to monolayer\textsuperscript{38,39}. A good illustration would be the study of Carver et al.\textsuperscript{40}. They demonstrated that the delivery of oligonucleotides with Lipofectamine lipoplex and PEI polyplex was significantly attenuated in spheroid models compared to monolayer cultures. Further, their results showed that only cells located at the periphery of the spheroid received the oligonucleotides.

**Conclusion**

In summary, we successfully developed a well-designed multi-targeted nanosystem using anti-HER2 VHH functionalized PAMAM, CXCR1 promoter, PE38 toxin and bFGF 5’UTR. This nanosystem was selectively internalized, specifically transcribed, efficiently translated and caused a selective cytotoxicity in HER2-positive BCSCs. Our data suggest that this novel multi-targeted nanosystem would be a potent strategy for selective cancer killer gene therapy.

We further demonstrated that the efficacy of our targeted gene therapy was lower in spheroid models compared to monolayer cultures, indicating that anticancer therapy assessments using spheroid might be more predictive of clinical efficacy than conventional monolayer cell culture.

**Declarations**

**Data Availability**

All data generated or analyzed during this study are included in this published article

**Acknowledgments**

The authors wish to thank Professor Ira Pastan (NIH) for kindly providing the plasmid encoding PE38 (pRB391).

**Authors’ contributions**
Cobra Moradian: Carried out the experiments, Analyzed and interpreted the results, Wrote the manuscript

Fatemeh Rahbarizadeh: Designed and supervised the project, Analyzed and interpreted the data, Revised the manuscript

**Competing interests**

The authors disclose no conflicts.

**References**

1. Dragu, D. L., Necula, L. G., Bleotu, C., Diaconu, C. C. & Chivu-Economescu, M. Therapies targeting cancer stem cells: Current trends and future challenges. *World journal of stem cells* **7**, 1185 (2015).

2. Dontu, G. *et al*. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. *Genes & development* **17**, 1253-1270 (2003).

3. Kreitman, R. J., Siegall, C. B., Chaudhary, V. K., FitzGerald, D. J. & Pastan, I. Properties of chimeric toxins with two recognition domains: interleukin 6 and transforming growth factor .alpha. at different locations in Pseudomonas exotoxin. *Bioconjugate Chemistry* **3**, 63-68, doi:10.1021/bc00013a010 (1992).

4. Candolfi, M. *et al*. Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics. *Proceedings of the National Academy of Sciences* **107**, 20021-20026 (2010).

5. Kimchi-Sarfaty, C. *et al*. SV40 Pseudovirion gene delivery of a toxin to treat human adenocarcinomas in mice. *Cancer gene therapy* **13**, 648 (2006).

6. McDermott, S. P. & Wicha, M. S. Targeting breast cancer stem cells. *Molecular Oncology* **4**, 404-419, doi:http://dx.doi.org/10.1016/j.molonc.2010.06.005 (2010).

7. Todorović-Raković, N. & Milovanović, J. Interleukin-8 in breast cancer progression. *Journal of Interferon & Cytokine Research* **33**, 563-570 (2013).

8. Duncan, R., Milburn, S. C. & Hershey, J. Regulated phosphorylation and low abundance of HeLa cell initiation factor eIF-4F suggest a role in translational control. Heat shock effects on eIF-4F. *Journal of Biological Chemistry* **262**, 380-388 (1987).

9. Fang, Y. X. *et al*. Development of chimeric gene regulators for cancer-specific gene therapy with both transcriptional and translational targeting. *Molecular biotechnology* **45**, 71-81 (2010).

10. Su, Y., Quan, X., Li, L. & Zhou, J. Computer simulation of DNA condensation by PAMAM dendrimer. *Macromolecular Theory and Simulations* **27**, 1700070 (2018).

11. Hu, Y., Liu, C. & Muyldermans, S. Nanobody-based delivery systems for diagnosis and targeted tumor therapy. *Frontiers in immunology* **8**, 1442 (2017).
12 Nikkhoi, S. K., Rahbarizadeh, F., Ahmadvand, D. & Moghimi, S. M. Multivalent targeting and killing of HER2 overexpressing breast carcinoma cells with methotrexate-encapsulated tetra-specific non-overlapping variable domain heavy chain anti-HER2 antibody-PEG-liposomes: in vitro proof-of-concept. *European Journal of Pharmaceutical Sciences* **122**, 42-50 (2018).

13 Slamon, D. *et al.* Human breast cancer: correlation of relapse and. *Science* **379**8106, 235 (1987).

14 Menard, S. *et al.* HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer. *Annals of oncology* **12**, S15-S19 (2001).

15 Slamon, D. J. *et al.* Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. *Science* **244**, 707-712 (1989).

16 Korkaya, H. *et al.* Regulation of mammary stem/progenitor cells by PTEN/Akt/β-catenin signaling. *PLoS Biol* **7**, e1000121 (2009).

17 Magnifico, A. *et al.* Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab. *Clinical Cancer Research* **15**, 2010-2021 (2009).

18 Korkaya, H., Paulson, A., Iovino, F. & Wicha, M. S. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. *Oncogene* **27**, 6120-6130 (2008).

19 Kelm, J. M., Timmins, N. E., Brown, C. J., Fussenegger, M. & Nielsen, L. K. Method for generation of homogeneous multicellular tumor spheroids applicable to a wide variety of cell types. *Biotechnology and bioengineering* **83**, 173-180 (2003).

20 Reshadmanesh, A., Rahbarizadeh, F., Ahmadvand, D. & Jafari Iri Soa, F. Evaluation of cellular and transcriptional targeting of breast cancer stem cells via anti-HER2 nanobody conjugated PAMAM dendrimers. *Artificial cells, nanomedicine, and biotechnology* **46**, S105-S115 (2018).

21 Jamnani, F. R. *et al.* Targeting high affinity and epitope-distinct oligoclonal nanobodies to HER2 over-expressing tumor cells. *Experimental cell research* **318**, 1112-1124 (2012).

22 Nikkhoi, S. K., Rahbarizadeh, F. & Ahmadvand, D. Oligo-clonal nanobodies as an innovative targeting agent for cancer therapy: new biology and novel targeting systems. *Protein Expression and Purification* **129**, 115-121 (2017).

23 Moradian, C. & Rahbarizadeh, F. Targeted Toxin Gene Therapy Of Breast Cancer Stem Cells Using CXCR1 Promoter And bFGF 5' UTR. *OncoTargets and therapy* **12**, 8809 (2019).

24 Snyder, S. L. & Sobocinski, P. Z. An improved 2, 4, 6-trinitrobenzenesulfonic acid method for the determination of amines. *Analytical biochemistry* **64**, 284-288 (1975).
25 Bailey, P. C. *et al.* Single-Cell Tracking of Breast Cancer Cells Enables Prediction of Sphere Formation from Early Cell Divisions. *iScience* **8**, 29-39 (2018).

26 Wan, X., Li, Z., Ye, H. & Cui, Z. Three-dimensional perfused tumour spheroid model for anti-cancer drug screening. *Biotechnology letters* **38**, 1389-1395 (2016).

27 Patra, B., Peng, C., Liao, W., Lee, C. & Tung, Y. (Nature Publishing Group, 2016).

28 Ivanov, D. P. *et al.* Multiplexing spheroid volume, resazurin and acid phosphatase viability assays for high-throughput screening of tumour spheroids and stem cell neurospheres. *PloS one* **9** (2014).

29 Yılmaz, Ö. & Sakarya, S. Is ‘Hanging Drop’ a Useful Method to Form Spheroids of Jlimt, Mcf-7, T-47d, Bt-474 That are Breast Cancer Cell Lines. *Single Cell Bio* **7**, 2 (2018).

30 Fant, K. *et al.* Effects of PEGylation and acetylation of PAMAM dendrimers on DNA binding, cytotoxicity and in vitro transfection efficiency. *Molecular pharmaceutics* **7**, 1734-1746 (2010).

31 Hama, S. *et al.* Overcoming the polyethylene glycol dilemma via pathological environment-sensitive change of the surface property of nanoparticles for cellular entry. *Journal of controlled release* **206**, 67-74 (2015).

32 Desoize, B. & Jardillier, J.-C. Multicellular resistance: a paradigm for clinical resistance? *Critical reviews in oncology/hematology* **36**, 193-207 (2000).

33 Nunes, A. S., Barros, A. S., Costa, E. C., Moreira, A. F. & Correia, I. J. 3D tumor spheroids as in vitro models to mimic in vivo human solid tumors resistance to therapeutic drugs. *Biotechnology and bioengineering* **116**, 206-226 (2019).

34 Mathis, J. M. *et al.* Cancer-specific targeting of an adenovirus-delivered herpes simplex virus thymidine kinase suicide gene using translational control. *The Journal of Gene Medicine: A cross-disciplinary journal for research on the science of gene transfer and its clinical applications* **8**, 1105-1120 (2006).

35 Pettersson, F. *et al.* Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer. *Clinical Cancer Research* **17**, 2874-2884 (2011).

36 Sorrells, D. L. *et al.* Detection of eIF4E gene amplification in breast cancer by competitive PCR. *Annals of surgical oncology* **5**, 232-237 (1998).

37 DeFatta, R. J., Chervenak, R. P. & De Benedetti, A. A cancer gene therapy approach through translational control of a suicide gene. *Cancer gene therapy* **9**, 505 (2002).
38 Galateanu, B. *et al.* Impact of multicellular tumor spheroids as an in vivo-like tumor model on anticancer drug response. *International journal of oncology* **48**, 2295-2302 (2016).

39 Grill, J. *et al.* The organotypic multicellular spheroid is a relevant three-dimensional model to study adenovirus replication and penetration in human tumors in vitro. *Molecular Therapy* **6**, 609-614 (2002).

40 Carver, K., Ming, X. & Juliano, R. L. Multicellular tumor spheroids as a model for assessing delivery of oligonucleotides in three dimensions. *Molecular Therapy-Nucleic Acids* **3**, e153 (2014).